title: Lithium administered by eye drops: a better treatment for bipolar affective disorder?
abstract: 1. Bipolar affective patients are supersensitive to light. 2. Lithium treatment decreases retinal sensitivity to light. 3. Recent findings concerning lithium perturbation of the function of various members of the G proteins family including transducin (G1), as well as findings of lithium sensitive hyperactive G proteins in mononuclear leukocytes of patients with mania led to the hypothesis that lithium sensitive hyperfunctional G1 is responsible for the supersensitivity to light in affective patients. 4. Thus, a change in the usual route of lithium administration into eye drops delivery is hypothesized to be more efficient clinically, with the advantages of shortening the time delay necessary to achieve therapeutic effects, and having less systemic side effects and reduced toxicity.
authors.affiliation: Department of Psychiatry, Beer-Sheva Mental Health Center, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Schreiber
authors.forename: S
authors.initials: S
authors.lastname: Avissar
mesh_terms: D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008094:Lithium / Q000008:administration & dosage* / Q000627:therapeutic use; D009883:Ophthalmic Solutions
chemical_list: D009883:Ophthalmic Solutions; D008094:Lithium